Multiple sclerosis and vitamin D: An update

European Journal of Clinical Nutrition

Volumn 58, Issue 8, 2004, Pages 1095-1109

  VanAmerongen, B M ^a   Dijkstra, C D ^a   Lips, P ^a   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone loss and fractures; Immunomodulation; Multiple sclerosis; Muscle weakness; Sunlight; Vitamin D metabolism; Vitamin D nutrition; Vitamin D status

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 19 NOR 1,25 DIHYDROXYERGOCALCIFEROL; 20 EPICALCITRIOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; COD LIVER OIL; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ERGOCALCIFEROL; MAGNESIUM; NITRIC OXIDE; OXYGENASE; PAMIDRONIC ACID; RAPAMYCIN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; AUTOCRINE EFFECT; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CELL FUNCTION; DEGENERATIVE DISEASE; DENDRITIC CELL; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ACTIVITY; FRACTURE; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; HORMONE ACTION; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; MACROPHAGE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; OSTEOLYSIS; PARACRINE SIGNALING; PREVALENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SEASONAL VARIATION; SUNLIGHT; T LYMPHOCYTE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ANIMALS; CALCITRIOL; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MULTIPLE SCLEROSIS; RATS; RISK FACTORS; SUNLIGHT; ULTRAVIOLET RAYS; VITAMIN D; VITAMIN D DEFICIENCY;

ANIMALIA;

EID: 4444308223     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1601952     Document Type: Review

References (162)

1. Acheson ED, Bachrach CD & Wright FM (1960): Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatr. Scand. 35, 132-147.
2. Adams JS, Singer FR, Gacad MA, Sharma OP, Hayes MJ, Vouros P & Holick MF (1985): Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endocrinol. Metab. 60, 960-966.
3. Agranoff BW & Goldberg D (1974): Diet and the geographical distribution of multiple sclerosis. Lancet 2, 1061-1066.
4. Alter M, Yamour M, Harshe M & Ed M (1974): Multiple sclerosis and nutrition. Arch. Neurol. 31, 267-272.
5. Amento EP & Cotter AC (1988): 1,25-Dihydroxyvitamin D3 augments antigen presentation by murine monocyte/macrophages. J. Bone Miner. Res. 3, S217.
6. Auer DP, Schumann EM, Kumpfel T, Gossl C & Trenkwalder C (2000): Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 47, 276-277.
7. Baas D, Prufer K, Ittel ME, Kuchler-Bopp S, Labourdette G, Sarlieve LL & Brachet P (2000): Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia 1, 59-68.
8. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC & Holick MF (1998): Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos. Int. 8, 222-230.
9. Bhalla AK, Amento EP, Clemens TL, Holick MF & Krane SM (1983): Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 57, 1308-1310.
10. Bhalla AK, Amento EP, Serog B & Glimcher LH (1984): 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J. Immunol. 133, 1748-1754.
11. Bjartmar C, Wujek JR & Trapp BD (2003): Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165-171.
12. Bouillon RA, Auwerx JH, Lissens WD & Pelemans WK (1987): Vitamin D status in the elderly: seasonal precursor deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am. J. Clin. Nutr. 45, 755-763.
13. Bouillon R, Okamura WH & Norman AW (1995): Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16, 200-257.
14. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M & Bouillon R (1995): Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J. Neuroimmunol. 61, 151-160.
15. Branisteanu DD, Mathieu C & Bouillon R (1997): Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. J. Neuroimmunol. 79, 138-147.
16. Brown A, Dusso A & Slatopolsky E (1999): Vitamin D. Am. J. Physiol. 277, F157-175.
17. Cantorna MT, Hayes CE & DeLuca HF (1996): 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93, 7861-7864.
18. Cantorna MT, Humpal-Winter J & DeLuca HF (1999): Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J. Nutr. 129, 1966-1971.
19. Cantorna MT, Woodward WD, Hayes CE & DeLuca HF (1998): 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 160, 5314-5319.
20. Casteels K, Bouillon R, Waer M & Mathieu C (1995): Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Curr. Opin. Nephrol. Hypertens. 4, 313-318.
21. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD & Meunier PJ (1992): Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med 327, 1637-1642.
22. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S & Meunier PJ (1997): Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 7, 439-443.
23. Chel VGM, Ooms ME, Popp-Snijders C, Pavel S, Schothorst AA, Meulemans CCE & Lips P (1998): Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. J. Bone Miner. Res. 13, 1238-1242.
24. Chesney RW, Rosen JF, Hamstra AJ, Smith C, Mahaffey K & DeLuca HF (1981): Absence of seasonal variation in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. J. Clin. Endocrinol. Metab. 53, 139-142.
25. Clemens TL, Adams JS, Henderson SL & Holick MF (1982): Increased skin pigment reduces the capacity of skin to synthesize vitamin D3. Lancet 1, 74-76.
26. Compston A (1997): Genetic epidemiology of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 62, 553-561.
27. Correa P, Segersten U, Hellman F, Akerstrom G & Westin G (2002): Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors - new prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 87, 5826-5829.
28. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V & Lindsay R (1998): Fracture history and bone loss in patients with MS. Neurology 51, 1161-1165.
29. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL & Tilton RG (1994): Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93, 2684-2690.
30. Cross AH, San M, Stern MK, Keeling RM, Salvemini D & Misko TP (2000): A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 107, 21-28.
31. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F & Panina-Bordignon P (1998): Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101, 252-262.
32. Dawson-Hughes B, Harris SS & Dallal GE (1997): Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am. J. Clin. Nutr. 65, 67-71.
33. DeLuca HF & Cantorna MT (2001): Vitamin D: its role and uses in immunology. FASEB J. 15, 2579-2585.
34. DeLuca HF, Hayes CE & Cantorna MT (2000) US5716946: multiple sclerosis treatment.
35. Docio S, Riancho JA, Perez A, Olmos JM, Amado JA & Gonzalez-Macias J (1998): Seasonal deficiency of vitamin D in children: a potential target for osteoporosis-preventing strategies? J. Bone Miner. Res. 13, 544-548.
36. Ebers GC (1994): Genetics and multiple sclerosis: an overview. Ann. Neurol. 36, S12-S14.
37. Ebers GC & Sadovnick AD (1994): The role of genetic factors in multiple sclerosis susceptibility. J. Neuroimmunol. 54, 1-17.
38. Embry AF, Snowdon LR & Vieth R (2000): Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 48, 271-272.
39. Esparza ML, Sasaki S & Kesteloot H (1995): Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am. J. Epidemiol. 142, 733-737.
40. Esvelt RP & De Luca HF (1981): Calcitroic acid: biological activity and tissue distribution studies. Arch. Biochem. Biophys. 206, 403-413.
41. Eyles D, Brown J, Mackay-Sim A, McGrath J & Feron F (2003): Vitamin D3 and brain development. Neuroscience 118, 641-653.
42. Feldman D, Glorieux FH & Pike JW eds. (1997): Vitamin D. San Diego: Academic Press.
43. Flemming JO, Hummel AL, Beinlich BR, Borowski BJ, Peebles T, Colburn M, Cook TD, Wendt GJ & DeLuca HL (2000): Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study. Neurology 54, A338.
44. Food and Nutrition Board (FNB), Institute of Medicine (1997): Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press.
45. Fraser DR (1995): Vitamin D. Lancet 345, 104-107.
46. Freedman DM, Dosemeci M & Alavanja MC (2000): Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 57, 418-421.
47. Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K & Tashiro K (1999): Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J. Neurol. Sci. 166, 47-52.
48. Gale CR & Martyn CN (1995): Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425-448.
49. Garcion E, Nataf S, Berod A, Darcy F & Brachet P (1997): 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol. Brain Res. 45, 255-267.
50. Garcion E, Sindji L, Montero-Menei C, Andre C, Brachet P & Darcy F (1998): Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 22, 282-294.
51. Garcion E, Sindji L, Nataf S, Brachet P, Darcy F & Montero-Menei CN (2003): Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D(3) leads to early effects within the central nervous system. Acta Neuropathol. 105, 438-448.
52. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F & Wion D (2002): New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13, 100-105.
53. Gascon-Barre M, Demers C, Ghrab O, Theodoropoulos C, Lapointe R, Jones G, Valiquette L & Menard D (2001): Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney. Clin. Endocrinol . 54, 107-115.
54. Genain CP & Hauser SL (1997): Autoimmune demyelinating diseases of the central nervous system. In Immunology of the nervous system, eds RW Keane, WF Hickey, pp 703-726. New York: Oxford University Press.
55. Gloth III FM, Gundberg CM, Hollis BW, Haddad Jr JG & Tobin JD (1995): Vitamin D deficiency in homebound elderly persons. JAMA 274, 1683-1686.
56. Goldberg P (1974a): Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part I: sunlight, dietary factors and epidemiology. Int. J. Environ. Studies 6, 19-27.
57. Goldberg P (1974b): Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 2: biochemical and genetic factors. Int. J. Environ. Studies 6, 121-129.
58. Goldberg P, Fleming MC & Picard EH (1986): Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses 21, 193-200.
59. Goldman R (1984): Introduction of a high phagocytic capability in P388D1, a macrophage-like tumor cell line, by 1a,25-dihydroxyvitamin D3. Cancer Res. 44, 11-19.
60. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM & Adorini L (2001): Regulatory t cells induced by 1alpha,25-dihydroxyvitamin d(3) and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167, 1945-1953.
61. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ & Kumar R (2001): Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 6800-6805.
62. Guillemant S, Guillemant J & Duntze P (1995): Comparison of the biochemical and hormonal acute effects of calcium salts. Osteoporos. Int. 5, 66-67.
63. Guillemant J, Taupin P, Le HT, Taright N, Allemandou A, Peres G & Guillemant S (1999): Vitamin D status during puberty in French healthy male adolescents. Osteoporos. Int. 10, 222-225.
64. Hammond SR, English DR & McLeod JG (2000): The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123, 968-974.
65. Hauser SL, Weiner HL, Che M, Shapiro ME, Gilles F & Letvin NL (1984): Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J. Immunol. 132, 1276-1281.
66. Hayes CE (2000): Vitamin D: a natural inhibitor of multiple sclerosis. Proc. Nutr. Soc. 59, 531-535.
67. Hayes CE, Cantorna MT & DeLuca HF (1997): Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216, 21-27.
68. Heaney RP (2003b): Long-latency deficiency disease: insights from calcium and vitamin D. Am. J. Clin. Nutr. 78, 912-919.
69. Heaney RP, Davies KM, Chen TC, Holick MF & Barger-Lux MJ (2003a): Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204-210.
70. Hewison M, Gacad MA, Lemire J & Adams JS (2001): Vitamin D as a cytokine and hematopoetic factor. Rev. Endocr. Metab. Disord. 2, 217-227.
71. Hewison M, Zehnder D, Bland R & Stewart PM (2000): 1alpha-Hydroxylase and the action of vitamin D. J. Mol. Endocrinol. 25, 141-148.
72. Hine TJ & Roberts NB (1994): Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D. Ann. Clin. Biochem. 31, 31-34.
73. Holick MF (1987): Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. Fed. Proc. 46, 1876-1882.
74. Holick MF (2002): Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr. Opin. Endocrinol. Diab. 9, 87-98.
75. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM & Dijkstra CD (1990): Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172, 1025-1033.
76. Hutter CD & Laing P (1996): Multiple sclerosis: sunlight, diet, immunology and aetiology. Med. Hypotheses 46, 67-74.
77. Issa LL, Leong GM & Eisman JA (1998): Molecular mechanism of vitamin D receptor action. Inflamm. Res. 47, 451-475.
78. Killestein J, Rep MH, Meilof JF, Ader HJ, Uitdehaag BM, Barkhof F, van Lier RA & Polman CH (2002): Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 58, 1077-1080.
79. Koeffler HP, Amatruda T, Ikekawa N, Kobayashi Y & DeLuca HF (1984): Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 44, 5624-5628.
80. Kumar R (1986): The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int. 30, 793-803.
81. Lauer K (1997): Diet and multiple sclerosis. Neurology 49, S55-S61.
82. Lehmann B, Tiebel O & Meurer M (1999): Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents - a preliminary study. Arch. Dermatol. Res. 291, 507-510.
83. Lemire JM & Adams JS (1992): 1,25-Dihydroxyvitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein-specific T cell clone. J. Bone Miner. Res. 7, 171-177.
84. Lemire JM & Archer DC (1991): 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103-1107.
85. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135, 2818-2821.
86. Lips P (2001): Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 22, 477-501.
87. Lips P, Netelenbos JC, Jongen MJ, van Ginkel FC, Althuis AL, van Schaik CL, van der Vijgh WJ, Vermeiden JP & van der Meer C (1982 : Histomorphometric profile and vitamin D status in patients with femoral neck fracture. Metab. Bone Dis. Relat. Res. 4, 85-93.
88. Lips P, Wiersinga A, van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD & van der Vijgh WJ (1988): The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J. Clin. Endocrinol. Metab. 67, 644-650.
89. Lucchinetti CF, Bruck W, Rodriquez M & Lassmann H (1996): Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259-274.
90. Malabanan A, Veronikis IE & Holick MF (1998): Redefining vitamin D insufficiency. Lancet 351, 805-806.
91. Mahon BD, Gordon SA, Cruz J, Cosman F & Cantorna MT (2003): Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134, 128-132.
92. 3 and the immune system. Mol. Cell. Endocrinol. 43, 113-122.
93. Martyn CN (1991): The epidemiology of multiple sclerosis. In McAlpine's Multiple Sclerosis, 2nd edn. WB Matthews ed. Edinburgh London Melbourne and New York: Churchill Livingstone.
94. Mathieu C & Adorini L (2002): The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 8, 174-179.
95. Mathieu C, Van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D & Bouillon R (2001): In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J. Bone Miner. Res. 16, 2057-2065.
96. Matsuoka LY, Wortsman J, MacLaughlin JA & Holick MF (1987): Sunscreens suppress cutaneous vitamin D3 synthesis. J. Clin. Endocrinol. Metab. 64, 1165-1168.
97. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina-Bordignon P & Adorini L (2000): Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur. J. Immunol. 30, 498-508.
98. McAlpine D (1961): The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 84, 186-203.
99. McKenna MJ (1992): Differences in vitamin D status between countries in young adults and the elderly. Am. J. Med. 93, 69-77.
100. Meehan TF & DeLuca HF (2002): The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 408, 200-204.
101. Mellanby E (1950): A Story of Nutritional Research. Effect of Some Dietary Factors on Bones and Nervous System. Baltimore: The Williams & Wilkins company.
102. Monteyne P, Bureau JF & Brahic M (1998): Viruses and multiple sclerosis. Curr. Opin. Neurol. 11, 287-291.
103. Montomoli C, Allemani C, Solinas G, Motta G, Bernardinelli L, Clemente S, Murgia BS, Ticca AF, Musu L, Piras ML, Ferrai R, Caria A, Sanna S & Porcu O (2002): An ecologic study of geographical variation in multiple sclerosis risk in central Sardinia, Italy. Neuroepidemiology 21, 187-193.
104. Murrell TG, Harbige LS & Robinson IC (1991): A review of the aetiology of multiple sclerosis: an ecological approach. Ann. Hum. Biol. 18, 95-112.
105. Nashold FE, Hoag KA, Goverman J & Hayes CE (2001): Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119, 16-29.
106. Nashold FE, Miller DJ & Hayes CE (2000): 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 103, 171-179.
107. Nataf S, Garcion E, Darcy F, Chabannes D, Muller JY & Brachet P (1996): 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 55, 904-914.
108. Need AG, Horowitz M, Morris HA & Nordin BC (2000): Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am. J. Clin. Nutr. 71, 1577-1581.
109. Nellestijn J & Dekker K (1998): Wereldklimaat Informatie - Professioneel (Versie 2.0), De Bilt: Koninklijk Nederlands Meteorologisch Instituut.
110. Neveu I, Naveilhan P, Menaa C, Wion D, Brachet P & Garabédian M (1994): Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J. Neurosci. Res. 38, 214-220.
111. Nieves J, Cosman F, Herbert J, Shen V & Lindsay R (1994): High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44, 1687-1692.
112. Niino M, Kikuchi S, Fukazawa T, Yabe I & Tashiro K (2002): No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J. Neuroimmunol. 127, 177-179.
113. Norman AW (2000): Vitamin D and Milk. http://vitamind.ucr.edu/milk.html.
114. Norman AW, Nemere I, Zhou LX, Bishop JE, Lowe KE, Maiyar AC, Collins ED, Taoka T, Sergeev I & Farach-Carson MC (1992): 1,25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J. Steroid. Biochem. Mol. Biol. 41, 231-240.
115. Norman JE, Kurtzke JF & Beebe GW (1983): Epidemiology of multiple sclerosis in US veterans: 2. Latitude, climate and the risk of multiple sclerosis. J. Chronic Dis. 36, 551-559.
116. Noseworthy JH (1999): Progress in determining the causes and treatment of multiple sclerosis. Nature 399, A40-A47.
117. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, Laureys J, Rutgeerts O, Saint-Arnaud R, Bouillon R & Mathieu C (2000 : Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin. Exp. Immunol. 120, 139-146.
118. Paterson PY & Hanson MA (1969): Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J. Immunol. 103, 1311-1316.
119. Penna G & Adorini L (2000): 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405-2411.
120. Pike JW (1991): Vitamin D3 receptors: structure and function in transcription. Annu. Rev. Nutr. 11, 189-216.
121. Pillai S, Bikle DD & Elias PM (1987): 1,25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. J. Biol. Chem. 263, 5390-5395.
122. Ponsonby AL, McMichael A & van der Mei I (2002): Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 181-182, 71-78.
123. Provvedini DM, Tsoukas CD, Deftos LJ & Manolagas SC (1983): 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 16, 1181-1183.
124. Pugliatti M, Sotgiu S, Solinas G, Castiglia P & Rosati G (2001): Multiple sclerosis prevalence among Sardinians: further evidence against the latitude gradient theory. Neurol. Sci. 22, 163-165.
125. Ramsaransing G, Maurits N, Zwanikken C & De Keyser J (2001): Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult. Scler. 7, 345-347.
126. Reichel H, Koeffler HP & Norman AW (1989): The role of vitamin D endocrine system in health and disease. N. Engl. Med. 320, 980-991.
127. Rockett KA, Brookes R, Udalova I, Vidal V, Hill A & Kwiatkowski D (1998): 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of mycobacterium tuberculosis in a human macrophage-like cell line. Infect. Immun. 66, 5314-5321.
128. Rovaris M, Comi G, Sormani MP, Wolinsky JS, Ladkani D & Filippi M (2001): Effects of seasons on magnetic resonance imaging - measured disease activity in patients with multiple sclerosis. Ann. Neurol. 49, 415-416.
129. Ruuls SR, Van Der Linden S, Sontrop K, Huitinga I & Dijkstra CD (1996): Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin. Exp. Immunol. 103, 467-474.
130. Scientific Committee on Food of the European Commission (SCF) (2002): Opinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin D. Luxembourg: European Commission.
131. Scharla SH (1998): Prevalence of subclinical Vitamin D deficiency in different European countries. Osteoporos. Int. 8, s7-s12.
132. Scharla SH, Scheidt-Nave C, Leidig G, Woitge H, Wuster C, Seibel MJ & Ziegler R (1996): Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study. Exp. Clin. Endocrinol. Diabetes 104, 289-292.
133. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL & Glorieux FH (1997): The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12, 1552-1559.
134. Stamp TCB (1975): Factors in human vitamin D nutrition and in the production and cure of classical rickets. Proc. Nutr. Soc. 34, 119-130.
135. Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C & Ebers GC (2000): Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 54, 729-732.
136. Swank RL (1953): Treatment of multiple sclerosis with low-fat diet. Arch. Neurol. Psych. 69, 91-103.
137. Swank RL, Lerstad O, Storm A & Barker J (1952): Multiple sclerosis in rural Norway: Its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246, 721-728.
138. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL & Finkelstein JS (1998): Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777-783.
139. Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD & Owens T (1998): Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extra-vasation from blood, are prevented in macrophage-depleted mice. J. Immunol. 161, 3767-3775.
140. Trapp BD, Bö L, Mörk S & Chang A (1999): Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98, 49-56.
141. Van den Berg H (1997): Bioavailability of vitamin D. Eur. J. Clin. Nutr. 51 (Suppl 1), S76-S79.
142. Van Der Mei IA, Ponsonby AL, Blizzard L & Dwyer T (2001): Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168-174.
143. Van Der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H & Kilpatrick T (2003): Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327, 316.
144. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A & Mathieu C (2003): Combination of a 1,25-dihydroxyvitamin D(3) analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 32, 397-404.
145. Van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R & Mathieu C (2000): Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 69, 1932-1942.
146. Van Noort JM & Amor S (1998): Cell biology of autoimmune diseases. Int. Rev. Cytol. 178, 127-206.
147. Verstuyf A, Segaert S, Verlinden L, Casteels K, Bouillon R & Mathieu C (1998): Recent developments in the use of vitamin D analogues. Curr. Opin. Nephrol. Hypertens. 7, 397-403.
148. Vieth R (1999): Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 69, 842-856.
149. Vieth R, Chan PR & MacFarlane GD (2001): Efficacy and safety of vitamin D3 intake exceeding the lowest observed effect level. Am. J. Clin. Nutr. 73, 288-294.
150. Vieth R, Ladak Y & Walfish PG (2003): Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 88, 185-191.
151. Walters MR (1992): Newly identified actions of the vitamin D endocrine system. Endocr. Rev. 13, 719-764.
152. Webb AR, DeCosta BR & Holick MF (1989): Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation. J. Clin. Endocrinol. Metab. 68, 882-887.
153. Webb AR & Holick MF (1988): The rol of sunlight in the cutaneous production of vitamin D3. Annu. Rev. Nutr. 8, 375-399.
154. White P & Cooke N (2000): The Multifunctional Properties and Characteristics of Vitamin D-binding Protein. Trends Endocrinol. Metab. 11, 320-327.
155. Willenborg DO, Staykova MA & Cowden WB (1999): Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. J. Neuroimmun. 100, 21-35.
156. Wortsman J, Matsuoka LY, Chen TC, Lu Z & Holick MF (2000): Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 72, 690-693.
157. Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J & Kato S (1999): Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through smad proteins. J. Biol. Chem. 274, 12971-12974.
158. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K & Kato S (1999): Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283, 1317-1321.
159. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM & Hewison M (2001): Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 86, 888-894.
160. Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, Cross AH & Hickey WF (1996): Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J. Neuroimmunol. 64, 123-133.
161. Zittermann A, Scheld K & Stehle P (1998): Seasonal variations in vitamin D status and calcium absorption do not influence bone turnover in young women. Eur. J. Clin. Nutr. 52, 501-506.
162. Zmuda JM, Cauley JA & Ferrell RE (2000): Molecular epidemiology of vitamin D receptor gene variants. Epidemiol. Rev. 22, 203-217.